Technology gives more power to expecting mums.

HeraMED ([ASX:HMD] is using disruptive technology to give more control to expecting parents, by providing mothers-to-be far greater pregnancy monitoring abilities along with digital connectivity to medical professionals and health care providers.

The Israeli-based, ASX listed company, has now announced that the Mayo Clinic, [considered one of the best medical centres in the world], is now partnering with it to develop a hospital/health care provider component of the HeraMED technology.

"The teams plan to build a comprehensive pregnancy App leveraging a machine learning-based algorithm that will potentially enable better management of diversified pregnancy situations, allowing better care at a lower cost." HeraMED announcement.

In simple terms, here's how HeraMED should ultimately work:

• HeraBEAT foetal heart rate monitor used by expectant mothers anytime, anywhere. [COMPLETED AND IN USE].

• Blood pressure, urine sample and weight also digitally inputted [UNDER DEVELOPMENT].

• All the above information is sent via smart phone app to cloud-based secure platform HeraCARE. [VERSION ONE COMPLETE AND IN TRIAL IN BRAZIL].

• All information accessed via HeraCARE platform by health care professionals in hospital, clinic or OBGYN of choice. [UNDER DEVELOPMENT MAYO CLINIC]

• Algorithmic systems monitor and track pregnancy data, watching for potential issues based on personalised user profile while adding anonymous data to general data base for more accurate service provision. [UNDER DEVELOPMENT WITH MAYO CLINIC]

• HeraBEAT allows social media access to other pregnant women, along with 24/7 digital access to midwife. [UNDER DEVELOPMENT]

As you can see from the above list, much of the HeraMED technology is in development, albeit, well advanced.

CEO David Groberman told me he believes, with the Mayo Clinic as a partner, the roll out of a trial version of the full HeraMED suite should happen by mid 2020.

Digitally transformative technologies often fall victim to overly optimistic delivery timeframes.

This happens not because the CEO is trying to maintain shareholder interest and confidence, although it is a constant temptation and balancing act, but because the delays and challenges in breaking new digital ground, is often not fully appreciated or even known until it is tried.

What is certain, based on HeraMED's ASX announcements is that the technology has:

• Initially attracted a small investment from the Mayo Clinic, and now a full blown partnership.

• Established sales distribution deals and channels for HeraBEAT that either are generating, or are about to generate sales in Australia, Germany, Israel and Britain.

• FDA approval process underway.

• HeraBEAT and HeraCARE platform [version 1] operational across multiple hospitals and clinics in South America [Used by Brazilian-based Hapvida, which operates medical insurance business, 100 hospitals and 1000 clinics in six states].

• Uploading and utilizing data at multiple Hapvida sites and thus showing potential scalability of HeraBEAT/HeraCARE as a Software as a Service solution.

I spoke with David Groberman about the Mayo Clinic partnership deal and what it means for HeraMED.

We do not recommend or advise to buy or sell shares in HeraMED. The InsideMarket Private Fund does not own shares in HeraMED at the time of publishing this post. We also have not received any payment from the company for this coverage. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.